Value Bridge — HONORHEALTH JOHN C. LINCOLN MED CTR
Current $-49M → Target $-35M (+$13.7M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-48.8M
Current EBITDA
$-35.1M
Target EBITDA
+$13.7M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$3.1M
Payer Mix Optimization
$7.4M
Cost to Collect Reduction
$2.5M
Clean Claim Improvement
$1.9M
Volume & Rate Growth
$12.4M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-49M to $-35M. The highest-impact lever is Volume & Rate Growth at $4.9M probability-weighted.
IC talking point: "We see $14M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $150M in equity value creation."